Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes
Open accessThe DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index, and 3 are not checked yet.
Abstract
Control of fatty acid storage and release in adipose tissue is fundamental in energy homeostasis and the development of obesity and type 2 diabetes. We here take the whole signalling network into account to identify how insulin and β-adrenergic stimulation in concert controls lipolysis in mature subcutaneous adipocytes obtained from non-diabetic and, in parallel, type 2 diabetic women. We report that, and show how, the anti-lipolytic effect of insulin can be fully explained by protein kinase B (PKB/Akt)-dependent activation of the phosphodiesterase PDE3B. Through the same PKB-dependent pathway β-adrenergic receptor signalling, via cAMP and PI3Kα, is anti-lipolytic and inhibits its own stimulation of lipolysis by 50%. Through this pathway both insulin and β-adrenergic signalling control phosphorylation of FOXO1. The dose–response of lipolysis is bell-shaped, such that insulin is anti-lipolytic at low concentrations, but at higher concentrations of insulin lipolysis was increasingly restored due to inhibition of PDE3B. The control of lipolysis was not altered in adipocytes from diabetic individuals. However, the release of fatty acids was increased by 50% in diabetes due to reduced reesterification of lipolytically liberated fatty acids. In conclusion, our results reveal mechanisms of control by insulin and β-adrenergic stimulation — in human adipocytes — that define a network of checks and balances ensuring robust control to secure uninterrupted supply of fatty acids without reaching concentrations that put cellular integrity at risk. Moreover, our results define how selective insulin resistance leave lipolytic control by insulin unaltered in diabetes, while the fatty acid release is substantially increased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Effect of akti1/2 on lipolysis. Adipocytes were pre-incubated without (blue) or with 20 µM akti1/2 for 60 min (brown), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and fatty acids (n = 5) (a) and glycerol (n = 4) (b) were determined in the medium, and cAMP (n = 4) (c), phosphorylation of PKB at Ser473 (n = 4) (d) and Thr308 (n = 4) (e) were determined in the cells. Indicated are P-values for the effect of akti1/2 in isoproterenol-stimulated cells (a–c). Representative immunoblots of one experiment are shown [blots in (d) and (e) are from the same experiment, hence identical β-tubulin blots].](https://figures.cochat.ai/paper-figures/778fc87f7a754ac6a228a0e778801126/insulin-and-adrenergic-receptors-mediate-lipolytic-and-anti-lipolytic-signalling-figure-4.jpg)






![Figure 11. Effect of A66 + akti1/2 and wortmannin + akti1/2 on lipolysis. Adipocytes were pre-incubated without (blue) (a–f), with 10 µM A66 + 20 µM akti1/2 (a–c) (green and brown), or with 0.5 µM wortmannin + 20 µM akti1/2 (d–f) (green and brown) for 30 min, when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and the phosphorylation of PKB at Ser473 (a and d) or Thr308 (b and e) was determined in the cells, and glycerol released to the medium was determined (c and f) (n = 5). Indicated are P-values for the effect of indicated inhibitors in isoproterenol-stimulated cells (c and f). Representative immunoblots of one experiment are shown [blots in (a) and (b), and in (d) and (e), respectively, are from the same experiment, hence identical β-tubulin blots].](https://figures.cochat.ai/paper-figures/bf4e473444d74832882e89135d202620/insulin-and-adrenergic-receptors-mediate-lipolytic-and-anti-lipolytic-signalling-figure-11.jpg)


![Figure 14. Control of lipolysis — normally and in T2D. Adipocytes from non-diabetic control subjects (blue) or patients with T2D (red) were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol (iso) was added and cells incubated for another 10 min. The indicated analyte was then determined in the medium (glycerol and fatty acids) or in the cells (cAMP, HSL phosphorylation). Individual subject characteristics and clinical data are presented in Supplementary Table S1. (a) Glycerol: six non-diabetic control subjects [mean age 65 years (range 46–86); mean BMI 24 kg/m2 (range 18–28)] and seven subjects with T2D [mean age 67 years (range 45–77); mean BMI 32 kg/m2 (range 28–40)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.2 mM (range 4.9–7.3); and a mean concentration of insulin of 5.8 mIU/l (range 2.0–11.0). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.2 mM (range 6.3–12); and a mean concentration of insulin of 22 mIU/l (range 5.9–69). Because absolute levels of fatty acid and glycerol released from the adipocytes varied between donors, in order to compare non-diabetic and diabetic cells, data are presented as % of release in the presence of isoproterenol only, in the non-diabetic cells; and in diabetic cells as % of the average release, of all experiments, in the presence of isoproterenol only in the non-diabetic cells. (b) cAMP: seven non-diabetic control subjects [mean age 65 years (range 40–78); mean BMI 26 kg/m2 (range 20–28)] and 10 subjects with T2D [mean age 69 years (range 45–83); mean BMI 33 kg/m2 (range 28–40)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.3 mM (range 5.0–8.7); and a mean concentration of insulin of 8.6 mIU/l (range 1.9–22). The diabetic subjects had a mean fasting plasma concentration of glucose of 8.9 mM (range 5.4–12); and a mean concentration of insulin of 15 mIU/l (range 5.9–39). (c) HSL phosphorylation: nine non-diabetic control subjects [mean age 64 years (range 44–86); mean BMI 25 kg/m2 (range 18–28)] and seven subjects with T2D [same as in (a)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.1 mM (range 4.9–7.3); and a mean concentration of insulin of 6.2 mIU/l (range 2.0–13.0). The diabetic subjects had a mean fasting plasma concentration of glucose and insulin the same as in (a). Representative immunoblots of HSL-P in (c) are shown for one non-diabetic and one diabetic subject. (d) Fatty acids: seven non-diabetic control subjects [mean age 69 years (range 53–86); mean BMI 24 kg/m2 (range 18–28)] and seven subjects with T2D [same as in (a)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.6 mM (range 4.9–7.5); and a mean concentration of insulin of 6.7 mIU/l (range 2.0–13.0). The diabetic subjects had a mean fasting plasma concentration of glucose and insulin the same as in (a). (e) The abundance of HSL was determined by SDS–PAGE and immunoblotting in adipocytes from 10 non-diabetic control subjects (blue) [mean age 46 years (range 34–73); mean BMI 24 kg/m2 (range 20–28)] and 10 subjects with T2D (red) [mean age 55 years (range 45–83); mean BMI 37 kg/m2 (range 31–43)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.0 mM (range 4.8–7.6); and a mean concentration of insulin of 3.9 mIU/l (range 1.6–9.1). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.0 mM (range 5.4–12.3); and a mean concentration of insulin of 31 mIU/l (range 6.0–173). d, diabetic; nd, non-diabetic. (f) Re-esterification was determined. Adipocytes from 18 non-diabetic control subjects (blue) [mean age 62 years (range 43–86); mean BMI 24 kg/m2 (range 20–28)] or seven subjects with T2D (red) [mean age 67 years (range 45–77); mean BMI 32 kg/m2 (range 28–40)] were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol was added and cells incubated for another 10 min. Cells were then separated from medium and fatty acids and glycerol were determined in the medium. The difference between glycerol and fatty acids released (triacylglycerol → 1 glycerol + 3 fatty acids) is defined as reesterification. The reesterification is calculated as % of released fatty acids that were reesterified: 100 × [(3 × glycerol − fatty acids)/3 × glycerol]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.1 mM (range 4.9–8.0); and a mean concentration of insulin of 7.0 mIU/l (range 2.0–16). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.2 mM (range 6.3–12.3); and a mean concentration of insulin of 22 mIU/l (range 5.9–69).](https://figures.cochat.ai/paper-figures/ae9544ecc43144f980b08a961fa1a5fe/insulin-and-adrenergic-receptors-mediate-lipolytic-and-anti-lipolytic-signalling-figure-14.jpg)
![Figure 15. Lipolytic control by βAR integrated in the insulin signalling network of human adipocytes. The integrated comprehensive signalling network of insulin and β-adrenergic acute signalling in human adipocytes that we have defined in isolated primary human adipocytes, normally and in T2D [23,25–28,31,62,80,81] and herein. Blue arrows denote insulin signalling and orange arrows denote signalling by the βAR. Hatched blue and orange arrows denote joint signalling by insulin and βAR. The thicker arrows represent signalling investigated herein. The red arrows indicate that the impaired signalling in T2D is due to attenuated mTORC1 signalling and attenuated fatty acid esterification. Long term regulation of protein levels via transcriptional or translational control is not included in the scheme, and it can be noted that in type 2 diabetes maximal stimulation of glucose uptake is reduced in type 2 diabetes, because of down-regulated levels of GLUT4 [82] that apparently is due to reduced levels of the transcription factor FOXO1 in T2D [24,27]. FOXO1, in turn, appears to be reduced by the attenuated mTORC1 signalling in T2D [27].](https://figures.cochat.ai/paper-figures/07c1eaceda3b4e5286ad65a83e303bde/insulin-and-adrenergic-receptors-mediate-lipolytic-and-anti-lipolytic-signalling-figure-15.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Most of the studies have shown greater plasma glycerol concentrations in women (79, 81, 165, 167, 174, 180, 188, 196, 198 , 220–222), while few studies reported no difference between sexes (26, 169, 172, 176, 178).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Abdominal subcutaneous adipose tissue exhibited greater rates of lipolysis compared to lower body fat during 30 minutes of cycling at 66% of VO2max intensity (220).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, conflicting results were observed in lower body lipolysis: while some studies revealed greater FFA release in women using femoral venous catheterization (176) others suggested similar glycerol release rates in men and women using subcutaneous microdialysis method (220).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies on upper body fat tissue have contradictory findings, with some reporting profound lipolysis in moderately fit women (220, 222) and others indicating no significant sex-based differences in athletic groups (180, 198).”
From Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans (2025) · cites this paper as [220]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., & Obin, M. S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500294-jlr200 · Cited by 2,529
Angiogenesis and Inflammation in Peritoneal Dialysis: The Role of Adipocytes
Shi, J., Yu, M., & Sheng, M. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000476017 · Cited by 1,403
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126
Fatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896
SHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855
Beavo, J. A., & Reifsnyder, D. H. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90066-h · Cited by 849
Cited by
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021) · Pharmaceuticals · doi:10.3390/ph14030238 · Cited by 250
“The other FFA receptor GPR119 expressed in β-cells is associated with a Gs protein, and it increases insulin secretion by rising the intracellular levels of cAMP [24].”
BackgroundInfluentialAdipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics
Yang, A., & Mottillo, E. P. (2020) · Biochemical Journal · doi:10.1042/bcj20190468 · Cited by 246
Mechanisms of insulin resistance related to white, beige, and brown adipocytes
Czech, M. P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.014 · Cited by 245
“Conversely, the role of insulin-sensitive Akt in regulating lipolysis has mixed support [127e131], and the ability of obesity to affect the cell autonomous pathway of lipolysis regulation via insulin as opposed to the re-esterification of fatty acids may be relatively small [103,129].”
BackgroundYe, R. Z., Richard, G., Gévry, N., Tchernof, A., & Carpentier, A. C. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab018 · Cited by 101
Interactions between insulin and exercise
Richter, E. A., Sylow, L., & Hargreaves, M. (2021) · Biochemical Journal · doi:10.1042/bcj20210185 · Cited by 99
Metadata
- Authors
- Jönsson, C., Castor Batista, A. P., Kjølhede, P., & Strålfors, P.
- Affiliations
- Linköping University (SE)
- Department of Clinical and Experimental Medicine, Linköping University, SE58185 Linköping, Sweden
- Corresponding author
- Strålfors, Peter
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2019-10-11
- Volume
- 476
- Issue
- 19
- Pages
- 2883-2908
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- PMC
- PMC6792037
- OpenAlex
- W2972545941
- Cited by
- 34
- References
- 87
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 9 · 2020: 8
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Biochemical Journal (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DiVA (Linkoping University) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- insulin signaling, beta-adrenergic receptors, lipolysis, type 2 diabetes, human adipocytes, PDE3B, Akt/protein kinase B, cyclic AMP, PI3Kα, FOXO1 phosphorylation, fatty acid release, fatty acid re-esterification, insulin resistance, energy homeostasis
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Aged, Aged, 80 and over, Cells, Cultured, Diabetes Mellitus, Type 2, Female, Humans, Insulin, Lipolysis, Middle Aged, Obesity, Receptors, Adrenergic, beta, Adipocytes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes. https://app.cochat.ai/papers/10.1042/bcj20190594
- The paper
- Jönsson, C., Castor Batista, A. P., Kjølhede, P., & Strålfors, P. (2019). Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes. Biochemical Journal. https://doi.org/10.1042/bcj20190594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.